Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core S&P 500 ETF (IVV) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

iShares Core S&P 500 ETFTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

iShares Core S&P 500 ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares Core S&P 500 ETF trades at $775.21, while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). Which is the better fit depends on your goals.

IVVVRTX
Sector
Broad Market / FactorHealth
52-Week High
$776.81$529.65
52-Week Low
$634.93$376.62
Market Cap
$132.79B
Enterprise Value
$126.92B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core S&P 500 ETF

IVV, tracking the S&P 500, trades at $776.81, up 0.6% with a bullish technical signal from moving averages. The ETF approaches resistance near $779-$784 amid strong institutional interest, including a 24.8% position increase by First Bank & Trust. Recent news highlights record highs and JPMorgan's raised 2026 target to 8,000, driven by AI-fueled earnings growth.

Outlook remains positive with S&P 500 earnings growth up 51.1% year-over-year, but risks include overbought conditions (RSI_6 at 94.32) and potential consolidation. Investor sentiment is greedy, yet weak market breadth and high valuations warrant caution for near-term volatility.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.

Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.

Read more on IVV

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX